Frontage Laboratories, Inc. (“Frontage”) and Telomir Pharmaceuticals, Inc. (“Telomir”) recently presented promising pre-clinical data for Telomir‘s lead development product at the National University Health System of Singapore (NUHS) Centre for Healthy Longevity Conference 2024. The data… Read More
Landos’ lead asset, NX-13, is a first-in-class, oral NLRX1 agonist in Phase 2 for the treatment of ulcerative colitis (UC) NORTH CHICAGO, IL & NEW YORK – AbbVie Inc. (NYSE: ABBV)… Read More
Acquisition reinforces Gilead’s leadership in developing innovative therapies for challenging liver diseases FOSTER CITY, CA – Gilead Sciences, Inc. (Nasdaq: GILD) announced the completion of the previously announced transaction to… Read More
MONTREAL, QC – Novartis Pharmaceuticals Canada Inc. (Novartis Canada) is deeply disappointed with the draft recommendations of the Canadian Drug Expert Committee (CDEC) issued by the Canadian Agency for Drugs… Read More
WELL achieved record annual revenue of $776.1 million for 2023, an increase of 36% compared to the prior year. WELL achieved record quarterly revenues of $231.2 million in Q4-2023, an… Read More
